Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
The chart shows the growth of an initial investment of $10,000 in Integer Holdings Corporation, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Integer Holdings Corporation (ITGR) has returned 10.82% so far this year and -21.70% over the past 12 months. Looking at the last ten years, ITGR has achieved an annualized return of 10.24%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ITGR
1M1.69%
6M-17.44%
YTD10.82%
1Y-21.70%
5Y-1.35%
10Y10.24%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Integer Holdings Corporation (ITGR) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
10.83%
0.60%
2.24%
-1.32%
2025
6.81%
-11.49%
-4.70%
7.98%
-5.73%
4.34%
-11.41%
0.10%
-3.52%
-37.24%
11.79%
9.62%
2024
3.57%
8.61%
5.93%
-4.33%
8.76%
-4.17%
1.88%
9.44%
0.76%
-4.78%
13.11%
-6.34%
2023
-4.87%
11.08%
3.97%
6.52%
-0.33%
7.94%
5.21%
-7.45%
-8.58%
4.08%
7.04%
13.57%
2022
-8.53%
7.73%
-3.56%
-6.27%
6.13%
-12.07%
-0.19%
-9.42%
-0.73%
-1.30%
18.36%
-7.75%
2021
-9.58%
19.43%
2.42%
1.68%
-4.41%
3.93%
3.10%
0.93%
-10.03%
-0.04%
-11.87%
5.04%
2020
5.20%
5.01%
-30.89%
24.66%
8.97%
-8.08%
-10.35%
4.34%
-14.37%
-1.33%
21.63%
11.51%
2019
8.25%
12.21%
-17.88%
-9.60%
1.13%
19.75%
2.83%
-17.87%
5.38%
1.75%
-3.07%
6.16%
2018
9.98%
2.20%
10.67%
-2.23%
20.44%
-2.56%
11.55%
11.67%
3.82%
-10.68%
17.54%
-15.13%
2017
8.54%
10.55%
9.09%
-8.70%
7.88%
8.81%
5.41%
-0.33%
11.07%
-5.63%
-1.12%
-6.31%
2016
-32.18%
8.37%
-10.15%
2.51%
29.00%
4.25%
Performance Indicators
The charts below present risk-adjusted performance metrics for Integer Holdings Corporation (ITGR) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ITGR compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Integer Holdings Corporation volatility is 1.82%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Liabilities And Equity (USD)
3.41B
3.08B
2.94B
2.79B
2.58B
2.37B
2.35B
2.33B
2.85B
2.83B
Equity Attributable To Parent (USD)
1.75B
1.62B
1.52B
1.42B
1.35B
1.27B
1.15B
1.06B
893.38M
725.24M
Equity Attributable To Noncontrolling Interest (USD)
Integer Holdings Corporation's stock has declined 28% over the past year. VP Corporate Controller Tom Thomas sold 825 shares worth $70,000 on March 13, 2026, representing 15.85% of his direct holdings. The article characterizes this as routine liquidity management rather than a loss of confidence. Despite revenue growth of 8% YoY to $1.85 billion in 2025, the company faces elevated leverage near 3.0x EBITDA, with investors focused on whether Integer can sustain margin expansion and balance sheet improvement.
The Motley Fool•Jonathan Ponciano
AI Insight
While the stock is down 28% YoY and leverage remains elevated at 3.0x EBITDA, the insider sale appears routine rather than indicative of lost confidence. The company showed solid fundamentals with 8% revenue growth, 13% adjusted operating income growth, and 21% adjusted EPS growth in 2025. The main concern is whether the company can sustain margin expansion and improve its balance sheet, making the outlook uncertain but not necessarily negative.
Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Molina Healthcare for failing to disclose adverse medical cost trends; and Soleno Therapeutics for misrepresenting the safety profile of its drug candidate DCCR, which resulted in a patient death.
GlobeNewswire Inc.•Grabar Law Office
AI Insight
Company allegedly overstated competitive position in EP manufacturing market, concealed sustained sales deterioration in key devices, and made false statements about business prospects lacking reasonable basis.
Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR; and Unicycive Therapeutics for overstating FDA manufacturing compliance readiness. Shareholders who purchased shares during specified periods may be eligible to seek corporate reforms and compensation.
GlobeNewswire Inc.•Grabar Law Office
AI Insight
Company allegedly overstated competitive position in EP manufacturing market, concealed sustained sales deterioration in two EP devices, and made false statements about business prospects and growth drivers.
Integer Holdings Corporation announced the appointment of James Flanagan and Aaron Kapito to its Board of Directors as independent directors. Aaron Kapito's appointment is connected to a cooperation agreement with investment firm Irenic Capital Management. The moves are intended to enhance Integer's focus on growth and value creation, with the company expecting organic sales growth to return to market levels in 2026 and above-market growth in 2027.
GlobeNewswire Inc.•
AI Insight
The appointment of experienced directors with strong financial and governance expertise, combined with the strategic partnership with Irenic Capital Management and management's confidence in returning to market-level organic sales growth in 2026 and above-market growth in 2027, signals positive momentum and enhanced governance oversight.
Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Corcept Therapeutics faces allegations of misrepresenting clinical trial data for its relacorilant drug, which received an FDA Complete Response Letter. Integer Holdings is accused of overstating its competitive position and concealing deteriorating sales. Kyndryl Holdings disclosed SEC investigations into cash management practices and internal control weaknesses. Molina Healthcare allegedly failed to disclose adverse medical cost trends and guidance risks.
GlobeNewswire Inc.•Grabar Law Office
AI Insight
Alleged material misstatements regarding competitive position in EP manufacturing market and concealment of sustained deterioration in device sales, undermining credibility of growth projections.
Integer Holdings Corporation announced that its executive leadership team will participate in three major investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Oppenheimer 36th Annual Healthcare MedTech & Services Conference (March 17), and KeyBanc Capital Markets Healthcare Forum (March 18). Live webcasts and replays will be available on the company's investor relations website.
GlobeNewswire Inc.•Not Specified
AI Insight
The company is actively engaging with investors through multiple prestigious conferences and recently reported strong financial performance with 8% sales growth and 21% adjusted EPS growth in 2025, demonstrating confidence in its market position and future outlook.
Irenic Capital Management sold 1,047,583 shares of Surgery Partners (SGRY) in Q4 2025, reducing its stake to just 0.09% of assets. The stock has declined 39.7% over the past year, underperforming the S&P 500 by 51.61 percentage points. While the company's operations remain solid with 6.6% revenue growth, concerns center on high leverage with net debt to EBITDA at 4.2x-4.6x in a higher rate environment.
The Motley Fool•Jonathan Ponciano
AI Insight
Listed as Irenic Capital's top holding at 13.7% of AUM ($99.11 million), indicating strong conviction and allocation priority by the fund manager.
Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.
The Motley Fool•Lawrence Rothman, Cfa
AI Insight
Listed as Irenic's largest holding ($99.1 million, 6.7% of AUM) but no specific news or context provided in the article regarding this position.
Integer Holdings (ITGR) stock rose over 2% on Friday following strong Q4 2025 earnings results and multiple analyst upgrades. Benchmark upgraded the stock to buy with a $95 price target, while Wells Fargo and Truist Securities raised their price targets. The company reported 5% year-over-year sales growth to $472 million and a 22% increase in non-GAAP net income to $62 million.
The Motley Fool•Eric Volkman
AI Insight
Company posted better-than-expected Q4 earnings with 5% revenue growth and 22% non-GAAP net income growth. Multiple analyst upgrades and price target increases were issued, including a hold-to-buy upgrade from Benchmark. The stock operates in a growing medical device sector benefiting from demographic trends.
A securities class action lawsuit has been filed against Integer Holdings Corporation for allegedly making materially false and misleading statements about its competitive position in the electrophysiology manufacturing market and overstating the growth potential of its EP devices. Investors who purchased Integer common stock between July 25, 2024 and October 22, 2025 may be entitled to compensation. The deadline to serve as lead plaintiff is February 9, 2026.
GlobeNewswire Inc.•Rosen Law Firm
AI Insight
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding its competitive position in the EP market, sales deterioration of key devices, and false characterization of growth prospects. These allegations indicate significant corporate governance and disclosure failures that resulted in investor losses.
